2022-2023年血液恶性瘤中的药物更新
1From UCHealth Blood Disorders and Cell Therapies Center, Aurora, Colorado.
Journal of the advanced practitioner in oncology
|September 19, 2024
概括
本综述涵盖了美国食品和药物管理局 (FDA) 最近对血液恶性瘤的批准,详细介绍了新疗法,它们的机制和副作用的管理策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 血液性恶性瘤是癌症治疗中未满足需求的重要领域.
- 最近的进展导致了新的治疗选择.
- 美国食品和药物管理局 (FDA) 在批准新的癌症药物方面发挥着至关重要的作用.
研究的目的:
- 总结一下美国食品和药物管理局 (FDA) 对2022年底至2023年底的血液恶性瘤的关键批准.
- 提供新疗法的概述,包括它们的指示和作用机制.
- 讨论与这些新疗法相关的不良事件的监测和管理.
主要方法:
- 美国食品和药物管理局 (FDA) 对血液恶性瘤的相关批准进行了审查.
- 在JADPRO Live 2023上提供的信息由Rebecca L. Rezac,药学博士,BCOP.
- 专注于在2022年底到2023年底之间批准的疗法.
主要成果:
- 确定了FDA批准的血液性恶性瘤的关键新疗法.
- 详细介绍了每种新疗法的具体适用情况.
- 讨论了作用机制和管理副作用的策略.
结论:
- 从2022年底到2023年底的期间,FDA对血液癌症治疗的批准显著.
- 了解这些新疗法,它们的作用和潜在的副作用对于临床医生来说至关重要.
- 有效的副作用管理对于优化新型血液癌症药物的患者结果至关重要.
相关概念视频
Bone Marrow Sampling and Transplants
313
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
313
Hematopoiesis
5.2K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.2K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Erythropoiesis
4.1K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.1K


